The Circadian Clock in Cancer Development and Therapy - Progress in Molecular Biology and Translational Science - page 262

or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm.
Am J Gastroenterol . 1993;88(10):1744-1748.
48. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast
cancer. J Natl Cancer Inst . 2001;93(20):1557-1562.
49. Rafnsson V, Tulinius H, Jonasson JG, Hrafnkelsson J. Risk of breast cancer in female
flight attendants: a population-based study (Iceland). Cancer Causes Control . 2001;12
(2):95-101.
50. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast
cancer in women participating in the nurses' health study. J Natl Cancer Inst . 2001;93

(20):1563-1568.
51. Stevens RG, Hansen J, Costa G, et al. Considerations of circadian impact for defining
'shift work' in cancer studies: IARC Working Group Report. Occup Environ Med .
2011;68(2):154-162.
52. Pukkala E, Aspholm R, Auvinen A, et al. Cancer incidence among 10,211 airline
pilots: a Nordic study. Aviat Space Environ Med . 2003;74(7):699-706.
53. Keith LG, Oleszczuk JJ, Laguens M. Circadian rhythm chaos: a new breast cancer
marker. Int J Fertil Womens Med . 2001;46(5):238-247.
54. Rich T, Innominato PF, Boerner J, et al. Elevated serum cytokines correlated
with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity pat-
terns in patients with metastatic colorectal cancer. Clin Cancer Res . 2005;11
(5):1757-1764.
55. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a pre-
dictor of breast cancer survival. J Natl Cancer Inst . 2000;92(12):994-1000.
56. Kim KS, Kim YC, Oh IJ, Kim SS, Choi JY, Ahn RS. Association of worse prognosis
with an aberrant diurnal cortisol rhythm in patients with advanced lung cancer. Chro-
nobiol Int . 2012;29(8):1109-1120.
57. Sephton SE, Lush E, Dedert EA, et al. Diurnal cortisol rhythm as a predictor of lung
cancer survival. Brain Behav Immun . 2012;30:S163-S170.
58. Innominato PF, Giacchetti S, Bjarnason GA, et al. Prediction of overall survival
through circadian rest-activity monitoring during chemotherapy for metastatic colo-
rectal cancer. Int J Cancer . 2012;131(11):2684-2692.
59. Wu HS, Davis JE, Natavio T. Fatigue and disrupted sleep-wake patterns in patients
with cancer: a shared mechanism. Clin J Oncol Nurs . 2012;16(2):E56-E68.
60. Levi F, Filipski E, Iurisci I, Li XM, Innominato P. Cross-talks between circadian timing
system and cell division cycle determine cancer biology and therapeutics. Cold Spring
Harb Symp Quant Biol . 2007;72:465-475.
61. Mormont MC, Waterhouse J, Bleuzen P, et al. Marked 24-h rest/activity rhythms are
associated with better quality of life, better response, and longer survival in patients with
metastatic colorectal cancer and good performance status. Clin Cancer Res . 2000;6
(8):3038-3045.
62. Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL. Expression of the cir-
cadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia . Oct
2007;9(10):797-800.
63. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of
the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis . 2005;26

(7):1241-1246.
64. Kuo SJ, Chen ST, Yeh KT, et al. Disturbance of circadian gene expression in breast
cancer. Virchows Arch . Apr 2009;454(4):467-474.
65. Dai H, Zhang L, CaoM, et al. The role of polymorphisms in circadian pathway genes in
breast tumorigenesis. Breast Cancer Res Treat . 2011;127(2):531-540.
66. Blask DE, Hill SM, Dauchy RT, et al. Circadian regulation of molecular, dietary, and
metabolic signaling mechanisms of human breast cancer growth by the nocturnal